Arcus Biosciences, Inc.
NYSEArcus Biosciences has gained 22% over the past month and 9% on the week, yet short sellers are simultaneously adding to positions at the fastest pace in months — a tension that defines the setup heading into August earnings. The short side has been unusually active. Short interest climbed nearly 30% over the past 30 days, reaching 10.8% of the free float — a level that qualifies as…
RCUS cost to borrow surges to 0.52% — up 726% in one week — after recent biotech analyst upgrades.
Snapshot as of 19 Jul 2026
Arcus Biosciences has gained 22% over the past month and 9% on the week, yet short sellers are simultaneously adding to positions at the fastest pace in months — a tension that defines the setup heading into August…
Arcus Biosciences enters the stretch before its June 11 earnings report carrying two conflicting signals: a fresh clinical collaboration with Bristol Myers Squibb that validates its HIF-2α inhibitor, casdatifan, and a…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for RCUS — free to start on ORTEX.
Sign up for free →Open RCUS on ORTEX